Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MIK665 + VOB560 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MIK665 | MIK-665|MIK 665|S64315 | MCL1 Inhibitor 18 | MIK-665 (S64315) inhibits MCL1, potentially resulting in increased apoptosis of MCL-1 expressing tumor cells (PMID: 32513939). | |
VOB560 | S 65487|S-65487|S65487|VOB 560|VOB-560 | BCL2 inhibitor 27 | VOB560 binds to and selectively inhibits Bcl2, potentially leading to induction of apoptosis and inhibition of tumor cell proliferation (Cancer Res 2021;81(13_Suppl):Abstract nr 1276). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04702425 | Phase I | MIK665 + VOB560 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | Terminated | USA | ITA | ISR | FIN | ESP | BEL | 3 |